MIT-Harvard Center of Cancer Nanotechnology Excellence

麻省理工学院-哈佛大学癌症纳米技术卓越中心

• 批准号: 7976489
• 负责人: ROBERT Samuel LANGER
• 金额: $ 229.54万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7976489
• 关键词: MIT; Harvard; Center; Cancer; Nanotechnology

The overall goal of this U54 application is to support a highly multidisciplinary team of expert chemists, engineers, biologists, material scientists and clinicians to develop and rapidly translate new nanotechnologies to better diagnose and treat cancer in the clinic. This team formed a Center for Cancer Nanotechnology Excellence (CCNE) in 2004 and over the past 5 years has shown extraordinary productivity through its integrated research programs and shared resources. The primary team includes investigators from Massachusetts Institute of Technology (MIT), Harvard Medical School (HMS), Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) and Harvard Faculty of Arts and Sciences (FAS). The CCNE thus effectively bridges programs in basic sciences at two Universities (MIT and Harvard) and clinical programs at leading Hospitals (MGH and BWH). The program will continue to be headed up by Dr. Robert Langer and Dr. Ralph Weissleder as Co-Pls. Dr. Langer is Institute Professor at MIT and member of the Koch Institute for Integrative Cancer Research at MIT (Kl). Dr. Weissleder is a Professor at Harvard Medical School, the Director of the Center for Systems Biology at MGH, a practicing clinician at MGH and a member of the Dana Farber Harvard Cancer Center. Public Health Relevance: With recent advances in nanotechnology and the introduction of some new nanomaterials into clinical trials, a myriad of opportunities are available to advance medical science and disease treatment. The translational goal is now to better control and manipulate emerging new materials by precisely configuring molecular structures, adding biological functionalities, decreasing or eliminating toxicities, and creating supramolecular

U54应用程序的总体目标是支持由专家化学家，工程师，生物学家，材料科学家和临床医生组成的高度多学科团队开发和快速转化新的纳米技术，以更好地诊断和治疗临床癌症。该团队于2004年成立了癌症纳米技术卓越中心（CCNE），并在过去5年中通过其综合研究计划和共享资源显示出非凡的生产力。主要研究小组包括来自马萨诸塞州理工学院（MIT）、哈佛医学院（HMS）、马萨诸塞州总医院（MGH）、布里格姆妇女医院（BWH）和哈佛文理学院（FAS）的研究人员。因此，CCNE有效地连接了两所大学（麻省理工学院和哈佛）的基础科学课程和领先医院（MGH和BWH）的临床课程。该计划将继续由罗伯特·兰格博士和拉尔夫·韦斯利德博士作为合作伙伴领导。Langer博士是麻省理工学院的研究所教授，也是麻省理工学院（Kl）科赫综合癌症研究所的成员。Weissleder博士是哈佛医学院的教授，MGH系统生物学中心主任，MGH执业临床医生和哈佛癌症中心的Dana Farber成员。 公共卫生相关性：随着纳米技术的最新进展和一些新的纳米材料进入临床试验，有无数的机会可以促进医学科学和疾病治疗。现在的翻译目标是通过精确配置分子结构，增加生物功能，减少或消除毒性，以及创建超分子，更好地控制和操纵新兴的新材料。